A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare Canberra. Cancer in Australia. Cancer Series; 2017. Number 101(Cat. no. CAN 100).
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–1380. doi:10.1056/NEJMra0802714
   PubMed Web of Science ®Google Scholar
• Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(1 Suppl):191–202. doi:10.1002/1097-0142(19950101)75:1+<191::aid-cncr2820751307>3.0.co;2-y
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001. doi:10.1200/JCO.2012.46.9270
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Kerr KM, Bunn PA Jr., et al. Molecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies. Clin Lung Cancer. 2018;19(4):331–339. doi:10.1016/j.cllc.2018.03.014
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN clinical practice guidelines in oncology. Non-Small Cell Lung Cancer (Version 6.2018); 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 18, 2018.
   Google Scholar
• Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18(4):1167–1176. doi:10.1158/1078-0432.CCR-11-2109
   PubMed Web of Science ®Google Scholar
• Ao MH, Zhang H, Sakowski L, et al. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol. 2014;45(5):926–934. doi:10.1016/j.humpath.2014.01.005
   PubMed Web of Science ®Google Scholar
• Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012;76(1):1–18. doi:10.1016/j.lungcan.2011.10.017
   PubMed Web of Science ®Google Scholar
• Koyi H, Branden E, Kasim I, Wilander E. Co-localisation of glandular and squamous cell markers in non-small cell lung cancer. Anticancer Res. 2018;38(6):3341–3346. doi:10.21873/anticanres.12600
   Web of Science ®Google Scholar
• Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4(10):1202–1211. doi:10.1097/JTO.0b013e3181b28fb9
   Web of Science ®Google Scholar
• Pelosi G, Fabbri A, Bianchi F, et al. DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012;7(2):281–290. doi:10.1097/JTO.0b013e31823815d3
   PubMed Web of Science ®Google Scholar
• Walia R, Jain D, Madan K, et al. p40 & thyroid transcription factor-1 immunohistochemistry: a useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category. Indian J Med Res. 2017;146(1):42–48. doi:10.4103/ijmr.IJMR_1221_15
   PubMedGoogle Scholar
• Siddaraju N. Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO classification of lung cancer. Indian J Med Res. 2017;146(1):8–10. doi:10.4103/ijmr.IJMR_1069_17
   Google Scholar
• Zachara-Szczakowski S, Verdun T, Churg A. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. Hum Pathol. 2015;46(5):776–782. doi:10.1016/j.humpath.2015.02.001
   PubMed Web of Science ®Google Scholar
• Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25(3):405–415. doi:10.1038/modpathol.2011.173
   PubMed Web of Science ®Google Scholar
• Lilo MT, Allison D, Wang Y, et al. Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. J Am Soc Cytopathol. 2016;5(3):123–132. doi:10.1016/j.jasc.2015.07.002
   Google Scholar
• Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117(15):3416–3423. doi:10.1002/cncr.25830
   PubMed Web of Science ®Google Scholar
• Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol. 2002;33(9):921–926. doi:10.1053/hupa.2002.126878
   PubMed Web of Science ®Google Scholar
• Gurda GT, Zhang L, Wang Y, et al. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clin Transl Med. 2015;4:16. doi:10.1186/s40169-015-0057-2
   Google Scholar
• Tran L, Mattsson JS, Nodin B, et al. Various antibody clones of Napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol. 2016;24(9):648–659. doi:10.1097/PAI.0000000000000235
   Google Scholar
• Nonaka D. Ancillary immunohistochemical techniques for the subclassification of non-small cell lung cancer. In: Moreira AL, Saqi A, editors. Diagnosing Non-Small Cell Carcinoma in Small Biopsy and Cytology. New York: Springer New York; 2015:77–95.
   Google Scholar
• Ikeda K, Clark JC, Shaw-White JR, Stahlman MT, Boutell CJ, Whitsett JA. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem. 1995;270(14):8108–8114. doi:10.1074/jbc.270.14.8108
   Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.0000000000000630
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24(10):1348–1359. doi:10.1038/modpathol.2011.92
   PubMed Web of Science ®Google Scholar
• Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136(2):155–162. doi:10.5858/arpa.2011-0232-OA
   Web of Science ®Google Scholar
• Bir F, Celiker D, Evyapan BF, Yaren A, Edirne T. New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma. Turk J Med Sci. 2016;46(6):1854–1861. doi:10.3906/sag-1501-68
   Web of Science ®Google Scholar
• Woo JS, Reddy OL, Koo M, Xiong Y, Li F, Xu H. Application of immunohistochemistry in the diagnosis of pulmonary and pleural neoplasms. Arch Pathol Lab Med. 2017;141(9):1195–1213. doi:10.5858/arpa.2016-0550-RA
   Web of Science ®Google Scholar
• Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136(2):163–171. doi:10.5858/arpa.2011-0320-OA
   PubMed Web of Science ®Google Scholar
• Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41(1):20–25. doi:10.1016/j.humpath.2009.06.014
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35(1):15–25. doi:10.1097/PAS.0b013e3182036d05
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang H, Peng Y, Tian B, Peng L, Zhang DC. DeltaNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol. 2014;7(7):4247–4253.
   Web of Science ®Google Scholar
• Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118(6):441–449. doi:10.1002/cncy.20108
   PubMed Web of Science ®Google Scholar
• El Hag M, Schmidt L, Roh M, Michael CW. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions. Diagn Cytopathol. 2016;44(4):299–304. doi:10.1002/dc.23442
   Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017;52(1):103–109.
   Google Scholar
• Yatabe Y, Dacic S, Borczuk AC, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol. 2019;14(3):377–407. doi:10.1016/j.jtho.2018.12.005
   PubMed Web of Science ®Google Scholar
• de Sá JPM. Applied Statistics: Using SPSS, Statistica, Matlab and R. Berlin. Berlin, Heidelberg: Springer; 2007.
   Google Scholar
• Smits AJ, Vink A, Tolenaars G, Herder GJ, Kummer JA. Different cutoff values for thyroid transcription factor-1 antibodies in the diagnosis of lung adenocarcinoma. Appl Immunohistochem Mol Morphol. 2015;23(6):416–421. doi:10.1097/PAI.0000000000000099
   Google Scholar
• Vidarsdottir H, Tran L, Nodin B, et al. Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol. 2018;150(6):533–544. doi:10.1093/ajcp/aqy083
   PubMed Web of Science ®Google Scholar
• NordiQC. Assessment Run 46 Thyroid Transcription Factor-1 (TTF-1). Denmark; 2016.
   Google Scholar
• Travis LB. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer; 2015.
   Google Scholar
• Klebe S, Swalling A, Jonavicius L, Henderson DW. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. J Clin Pathol. 2016;69(2):136–141. doi:10.1136/jclinpath-2015-203184
   PubMed Web of Science ®Google Scholar
• Ikeda S, Naruse K, Nagata C, et al. Immunostaining for thyroid transcription factor 1, Napsin A, p40, and cytokeratin 5 aids in differential diagnosis of non-small cell lung carcinoma. Oncol Lett. 2015;9(5):2099–2104. doi:10.3892/ol.2015.3045
   Web of Science ®Google Scholar
• Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009;37(3):178–183. doi:10.1002/dc.20975
   Web of Science ®Google Scholar
• Agackiran Y, Ozcan A, Akyurek N, Memis L, Findik G, Kaya S. Desmoglein-3 and Napsin A double stain, a useful immunohistochemical marker for differentiation of lung squamous cell carcinoma and adenocarcinoma from other subtypes. Appl Immunohistochem Mol Morphol. 2012;20(4):350–355. doi:10.1097/PAI.0b013e318245c730
   Google Scholar